MorphoSys (MOR) News Today → Proof that the Musk/Bezos rivalry is about to hit a new level (From InvestorPlace) (Ad) Free MOR Stock Alerts €66.75 -0.05 (-0.07%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartHeadlinesStock AnalysisChartHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMorphoSys (ETR:MOR) Shares Down 0.1% marketbeat.com - May 9 at 12:21 AMUPDATE 2-Novartis to buy radiology drug specialist Mariana for $1 billionfinance.yahoo.com - May 2 at 10:19 AMMorphoSys: Hold Rating Until The Novartis Deal Closesseekingalpha.com - April 30 at 9:06 PMGermany stocks mixed at close of trade; DAX down 0.16%msn.com - April 29 at 2:42 PMNew safety risk for MorphoSys drug could complicate Novartis deal - STATmsn.com - April 28 at 9:06 PMMorphoSys earnings: here's what Wall Street expectsmarkets.businessinsider.com - April 28 at 9:14 AMMorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meetingfinance.yahoo.com - April 24 at 12:17 PMMorphoSys (ETR:MOR) Reaches New 12-Month High at $68.00marketbeat.com - April 17 at 7:36 PMGerman biopharma MorphoSys recommends Novartis offer be acceptedmsn.com - April 11 at 5:48 PMNovartis Pharma AG: Novartis tender offer for MorphoSys AG commencesfinanznachrichten.de - April 11 at 7:47 AMNovartis tender offer for MorphoSys AG commencesfinance.yahoo.com - April 11 at 7:47 AMNovartis commences tender offer for MorphoSysmsn.com - April 11 at 7:47 AMNovartis begins tender offer for cancer-focused MorphoSysmsn.com - April 11 at 7:47 AMUPDATE 2-Novartis begins tender offer for cancer-focused MorphoSysfinance.yahoo.com - April 11 at 7:47 AMNovartis: Higher Guidance, Now A Buyseekingalpha.com - April 4 at 3:32 AMMorphoSys (ETR:MOR) Sets New 52-Week High at $67.30marketbeat.com - April 2 at 7:48 PMEQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Actmarkets.businessinsider.com - March 22 at 7:54 AMMorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 15 at 1:28 PMEQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updatemarkets.businessinsider.com - March 13 at 6:55 PMMorphoSys: Q4 Earnings Insightsbenzinga.com - March 13 at 6:55 PMGerman regulators approve Novartis deal to buy drugmaker Morphosysmsn.com - March 12 at 9:48 AMWhat Makes MorphoSys AG Unsponsored ADR (MOR) a Strong Momentum Stock: Buy Now?finance.yahoo.com - February 15 at 3:09 PMBiotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & Morefinance.yahoo.com - February 8 at 2:17 PMMorphoSys just downgraded at JMP Securities, here's whyrealmoney.thestreet.com - February 7 at 2:39 AMNovartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology Drugfinance.yahoo.com - February 6 at 3:20 PMNovartis And MorphoSys Are A Perfect Matchseekingalpha.com - February 6 at 10:20 AMNovartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cashfinance.yahoo.com - February 5 at 6:41 PMUPDATE 1-Novartis to acquire cancer drug developer MorphoSys for $2.9 blnfinance.yahoo.com - February 5 at 6:41 PMMorphoSys AG ADR MORmorningstar.com - February 3 at 6:26 PMDAX Edges Higher As Investors Await GDP Datamarkets.businessinsider.com - January 31 at 7:45 PMUS Futures Flat, European Stocks Slightly Down Ahead of Central Bank Decisionsmarketwatch.com - January 30 at 5:51 PMEuropean Shares Slightly Higher; Flash Eurozone GDP Data Awaitedmarkets.businessinsider.com - January 30 at 5:51 PMMorphoSys expects 2024 Monjuvi U.S. net product sales in $80M - $95M rangemsn.com - January 30 at 8:28 AMMorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liabilityfinance.yahoo.com - January 30 at 8:28 AMMorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liabilityfinance.yahoo.com - January 30 at 8:28 AMMorphoSys: Positive Pelabresib Data Finally Unlocking Upsideseekingalpha.com - January 18 at 11:36 AMEQS-News: MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conferencemarkets.businessinsider.com - January 8 at 7:46 AMMorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 8 at 7:46 AMOptimistic Investors Push MorphoSys AG (ETR:MOR) Shares Up 48% But Growth Is Lackingfinance.yahoo.com - December 18 at 12:17 AMMorphoSys To Issue 3.423 Mln New Shares At EUR 30/shrmarkets.businessinsider.com - December 14 at 7:27 AMMorphoSys Shares Fall After Raising Funds to Accelerate Drug Launch, Trialsmarketwatch.com - December 14 at 7:27 AMEQS-Adhoc: Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Processmarkets.businessinsider.com - December 13 at 5:22 PMBuy Rating on Morphosys Ag Backed by Pelabresib’s Breakthrough Efficacy in Myelofibrosis Treatmentmarkets.businessinsider.com - December 12 at 7:44 AMBuy Rating on Morphosys Ag Backed by Strong MANIFEST-2 Trial Results and FDA Approval Potentialmarkets.businessinsider.com - December 11 at 8:02 PMMorphoSys climbs after late-stage data for blood cancer therapymsn.com - December 11 at 3:02 PMMorphoSys : Pelabresib Improves All Four Hallmarks Of Myelofibrosis In Phase 3 Studymarkets.businessinsider.com - December 11 at 12:17 AMMorphosys AG - ADR (MOR) Price Target Increased by 86.05% to 16.88msn.com - November 27 at 6:44 PMWhy Is Cancer Focused MorphoSys Stock Trading Lower Today?markets.businessinsider.com - November 21 at 1:49 PMStocks to Watch: Symbotic, MorphoSys, Agilent Technologiesmarketwatch.com - November 20 at 7:14 PMMorphoSys: Buying Constellation Was A Desperate Measureseekingalpha.com - November 20 at 2:14 PM Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Email Address The Crypto 9-5 Escape Plan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market. Click here to get instant access to the guide MOR Media Mentions By Week MOR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MOR News Sentiment▼0.050.36▲Average Medical News Sentiment MOR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MOR Articles This Week▼11▲MOR Articles Average Week Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Evotec News Today Gerresheimer News Today CompuGroup Medical SE & Co. KGaA News Today Carl Zeiss Meditec News Today Medigene News Today Genfit News Today Stratec News Today Drägerwerk AG & Co. KGaA News Today Fielmann Group News Today Fresenius SE & Co. KGaA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ETR:MOR) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
